ifm 2018-02: ixazomib daratumumab in elderly frail patients with r/r multiple myeloma
Published 2 years ago • 304 plays • Length 4:23Download video MP4
Download video MP3
Similar videos
-
0:52
the future of daratumumab in multiple myeloma
-
1:58
treatment options for patients with multiple myeloma who are resistant to daratumumab
-
4:01
choosing between isatuximab & daratumumab in multiple myeloma
-
1:37
daratumumab vs isatuximab in the treatment of multiple myeloma
-
2:30
daratumumab and isatuximab in the treatment of multiple myeloma
-
1:51
darazadex: a phase ii trial of daratumumab plus azacitidine and dexamethasone in r/r myeloma
-
1:00
the recent fda approval of teclistamab for r/r multiple myeloma
-
6:07
blood analysis in multiple myeloma
-
14:04
2016 national conference: dr sebag- daratumumab for the treatment of myeloma
-
2:37
statistics of multiple myeloma
-
12:57
darzalex faspro® (daratumumab and hyaluronidase-fihj) mechanism of action for multiple myeloma
-
3:57
daratumumab in the treatment of mm with high-risk cytogenetics
-
5:07
daratumumab in the management of al amyloidosis
-
1:35
rationale for using immunotherapies in the frontline treatment of multiple myeloma
-
0:52
mrd for multiple myeloma: is it ready for prime-time?
-
13:43
darzalex® iv (daratumumab) mechanism of action for multiple myeloma
-
3:56
iv daratumumab in r/r myeloma: bodyweight analysis
-
1:09
the efficacy & role of iberdomide in r/r multiple myeloma
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma